- Home
- RYTM
as 12-20-2024 4:00pm EST
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 3.1B | IPO Year: | 2017 |
| Target Price: | $65.80 | AVG Volume (30 days): | 552.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.17 - $68.58 | Next Earning Date: | 11-05-2024 |
| Revenue: | $112,530,000 | Revenue Growth: | 81.55% |
| Revenue Growth (this year): | 63.64% | Revenue Growth (next year): | 42.98% |
Stock Insider Trading Activity of Rhythm Pharmaceuticals Inc. (RYTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Nov 11 '24 | Sell | $67.15 | 66,861 | $4,434,882.42 | 1,172 | |
| Shulman Joseph | RYTM | Chief Technical Officer | Nov 11 '24 | Sell | $66.87 | 13,281 | $882,340.74 | 0 | |
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Nov 6 '24 | Sell | $62.50 | 9,375 | $585,940.00 | 13,500 |
Latest Rhythm Pharmaceuticals Inc. News
RYTM Breaking Stock News: Dive into RYTM Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Rhythm Pharmaceuticals Gains FDA Approval for Expanded IMCIVREE Use
Benzinga
a day ago
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
GlobeNewswire
a day ago
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
MT Newswires
2 days ago
Oppenheimer Initiates Coverage on Rhythm Pharmaceuticals With Outperform Rating, $76 Price Target
TipRanks
16 days ago
Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities
MT Newswires
19 days ago
Rhythm Pharmaceuticals Says Imcivree Receives Expanded Marketing Authorization in UK
GlobeNewswire
19 days ago
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old
Investor's Business Daily
a month ago
Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone
Compare RYTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RYTM Rhythm Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.